Filing Flows › Interpace Biosciences (IDXG) › Operating margin
Interpace Biosciences (IDXG) operating margin by quarter
Interpace Biosciences' operating margin was 3.5% in Q2 2026 (second quarter 2026), -8.9 pts from Q1 2026. Over the last 6 quarters it ranged from 3.5% (Q2 2026) to 17.1% (Q4 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | 3.5% | -8.9 pts | — |
| Q1 2026 | 12.4% | -4.7 pts | -3.5 pts |
| Q4 2025 | 17.1% | +4.0 pts | +0.5 pts |
| Q3 2025 | 13.1% | -2.8 pts | — |
| Q1 2025 | 15.9% | -0.7 pts | — |
| Q4 2024 | 16.6% | — | — |
Q2 2026 at a glance
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
Questions
What is Interpace Biosciences' operating margin?
Interpace Biosciences' operating margin was 3.5% in Q2 2026 (second quarter 2026), -8.9 pts from Q1 2026.
How has Interpace Biosciences' operating margin changed?
Over the last 6 quarters it ranged from 3.5% (Q2 2026) to 17.1% (Q4 2025).